Skip to content
MARKETS / BALCAO / ZOMDF
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Zomedica Corp. ZOMDF

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$32.0M
▲ 17.4% YoY
$-81.9M
$-18.2M
In brief

What this company does

We are an animal health company creating and marketing products for companion animals, including dogs, cats and horses, by focusing on the unmet needs of clinical veterinarians. We are currently commercializing six product lines, consisting of diagnostic and therapeutic devices, that meet our objectives of improving the quality of care for the pet and the satisfaction of the pet parent, as well as the workflow, cashflow and profitability of the veterinarian’s practice. As of December 31, 2025, we had 141 employees. None of our employees are represented by labor unions or covered by collective bargaining agreements.

Written from the business description in Zomedica Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth
USD 32.0M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 32.0 · Net income -81.9
20M-40M-80M2016201720182019202020212022202320242025
Compound annual growth
+19.2%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−256 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -263.4% · Net -255.6%
-200%-400%2016201720182019202020212022202320242025
ROE
FY2025 · ROE -52.6%
-200%-400%-600%2016201720182019202020212022202320242025

Each USD of equity lost 53 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -18.2
-10M-20M2016201720182019202020212022202320242025

Total assetsUSD 127.0M
EquityUSD 115.4M
CashUSD 9.0M
Current ratio6.78×

Equity funds 91% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.0····
Operating income $B−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.0−0.0−0.0−0.0−0.00.0····
Net income $B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.08−0.05−0.04−0.02−0.05−0.05−0.19−0.18−0.09−0.07
Dividend / sh $··········
Payout %··········
ROE %−52.6−21.6−13.6−6.3−11.4−63.6−687.8−413.9−196.2−149.7
Shares out B0.980.980.980.980.980.640.110.100.090.08

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 46 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 49 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inoutside the United States — SEC code A0
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image